Do you have locally advanced, inoperable, node-positive non-small cell lung cancer (NSCLC), stage II or III? If so, you may be able to take part in a study to learn more about the effectiveness of adding stereotactic body radiation therapy (SBRT) to the standard treatment of radiation and chemotherapy.

Have you been diagnosed with cancer or a benign disease that is being evaluated for cancer for which you may receive treatment? If so, you may be able to take part in a research study that collects biospecimens (e.g. blood, saliva, tissue, etc) and health information to better understand how cancers develop and affect the body,]. If so, you may be able to take part in a research study that aims to identify non-invasive biomarkers for cervical cancer screening and monitoring following treatment of abnormal areas on the cervix caused by HPV.

The purpose of this study is to understand how monitoring symptoms at home after lung cancer diagnosis could impact quality of care and the likelihood of returning to the hospital. This study will also help us understand whether symptom monitoring in patients with advanced lung cancer is helpful for patients and the clinical teams who care for them.

Have you been diagnosed with pleural fluid, and have been referred for a pleural fluid drainage? If so, you may be able to participate in a research registry to help us learn more about lung cancer.

Have you been diagnosed with Advanced Prostate Cancer? If so, you may be able to take part in an International Registry for Men.

Have you ever been diagnosed with metastatic triple negative breast cancer and received 2 or less lines of chemotherapy for your metastatic disease? If so you may be eligible for a trial to evaluate different treatment combination with avelumab for your metastatic breast cancer.

Have you recently been diagnosed with breast cancer but have not yet started treatment (other than surgery)? You may be able to take part in the UNC CogMAP study. In this study, we want to learn more about cognitive and brain function before and after cancer treatment. This will help us to better understand risk factors for experiencing cognitive difficulties during and after treatment.

This study is assessing the effectiveness and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when given with atezolizumab and bevacizumab as a first-line treatment for unresectable, locally advanced or metastatic patients with hepatocellular carcinoma (HCC). TIGIT is thought to play an important role in HCC's response to immunotherapy treatments such as atezolizumab. This study will assess whether the addition of tiragolumab to atezolizumab and bevacizumab will improve response and clinical outcomes.

In this study, we want to learn if decreasing or increasing your radiation and hormonal therapy has an effect on high risk prostate cancer.

The study involves research of three study drugs, given alone or in combination. The combination of the study drugs is referred to as T-Plex. The purpose of the study is to learn if the study drugs are well tolerated and effective in treating your type of cancer.